Quick Answer
Vera Therapeutics, Inc. reported Net Income Loss of -$299.62 million for the year ending 2025.
- Vera Therapeutics, Inc. showed a decrease of -96.9% in Net Income Loss from 2024 to 2025.
- This data is from Vera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$2.47 million | Q2 2020: -$3.60 million | Q3 2020: -$4.46 million | Q1 2021: -$4.71 million | Q2 2021: -$3.44 million | Q3 2021: -$7.61 million | Q1 2022: -$17.09 million | Q2 2022: -$14.85 million | Q3 2022: -$24.68 million | Q1 2023: -$30.07 million | Q2 2023: -$20.16 million | Q3 2023: -$20.10 million | Q1 2024: -$28.38 million | Q2 2024: -$33.71 million | Q3 2024: -$46.63 million | Q1 2025: -$51.69 million | Q2 2025: -$76.53 million | Q3 2025: -$80.29 million.
- Over the full 6 years of available data (2020 to 2025), Vera Therapeutics, Inc.'s Net Income Loss has declined by 460.9%.
- Historical annual values: Fiscal year 2025: -$299.62 million | Fiscal year 2024: -$152.15 million | Fiscal year 2023: -$95.99 million | Fiscal year 2022: -$89.06 million | Fiscal year 2021: -$32.61 million | Fiscal year 2020: -$53.41 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: